Value of gene polymorphisms as markers of 5-FU therapy response in stage III colon carcinoma: a pilot study

被引：10
|
作者：
Farina-Sarasqueta, Arantza [1 ,2 ]
van Lijnschoten, Gesina [1 ]
Rutten, Harm J. T. [3 ]
van den Brule, Adriaan J. C. [1 ]
机构：
[1] PAMM Lab Pathol, Dept Mol Diagnost, NL-5623 EJ Eindhoven, Netherlands
[2] Fontys Univ Appl Sci, Dept Appl Sci, NL-5612 MA Eindhoven, Netherlands
[3] Catharina Hosp, Dept Surg, NL-5623 EJ Eindhoven, Netherlands
来源：
CANCER CHEMOTHERAPY AND PHARMACOLOGY | 2010年 / 66卷 / 06期
关键词：
5-FU; Colon carcinoma; OPRT; DPYD; TYMS; TYMP; SNP; OROTATE PHOSPHORIBOSYL TRANSFERASE; 5-FLUOROURACIL-BASED ADJUVANT CHEMOTHERAPY; THYMIDYLATE SYNTHASE EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; COLORECTAL-CANCER PATIENTS; DIHYDROPYRIMIDINE DEHYDROGENASE; PROGNOSTIC IMPACT; METASTASIS; RESECTION; EFFICACY;
D O I：
10.1007/s00280-010-1403-0
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The role of pharmacogenetics in chemotherapy response in colon carcinoma is controversial. We studied the value of known SNPs in genes involved in 5-FU metabolism as biomarkers of chemotherapy response in patients with stage III colon carcinoma. DNA was isolated from normal colonic tissue of 60 patients with stage III colon carcinoma treated adjuvantly with 5-FU combined with leucovorin. The tested SNPs were validated SNPs on the OPRT, TYMS and DPYD genes and a synonymous SNP on the TYMP gene. Real-time PCR, sequencing and RFLP were used for genotyping. None of the studied genotypes was associated with any of the tumor or patient characteristics. Moreover, none of the genotypes studied had effect on patient survival. In conclusion, the tested SNPs are not biomarkers of chemotherapy response in our stage III colon cancer patients group.
引用
收藏
页码：1167 / 1171
页数：5
相关论文
共 50 条
  • [1] Value of gene polymorphisms as markers of 5-FU therapy response in stage III colon carcinoma: a pilot study
    Arantza Fariña-Sarasqueta
    Gesina van Lijnschoten
    Harm J. T. Rutten
    Adriaan J. C. van den Brule
    Cancer Chemotherapy and Pharmacology, 2010, 66 : 1167 - 1171
  • [2] TS gene polymorphisms are not good markers of response to 5-FU therapy in stage III colon cancer patients
    Farina-Sarasqueta, A.
    Gosens, M. J. E. M.
    Moerland, E.
    van Lijnschoten, I.
    Lemmens, V. E. P. P.
    Slooter, G. D.
    Rutten, H. J. T.
    van den Brule, Adriaan J. C.
    CELLULAR ONCOLOGY, 2011, 34 (04) : 327 - 335
  • [3] TS gene polymorphisms are not good markers of response to 5-FU therapy in stage III colon cancer patients
    A. Fariña-Sarasqueta
    M. J. E. M. Gosens
    E. Moerland
    I. van Lijnschoten
    V. E. P. P. Lemmens
    G. D. Slooter
    H. J. T. Rutten
    Adriaan J. C. van den Brule
    Cellular Oncology, 2011, 34 : 327 - 335
  • [4] TS gene polymorphisms are not good markers of response to 5-FU therapy in stage III colon cancer patients
    Farina-Sarasqueta, A.
    Gosens, M. J. E. M.
    Moerland, E.
    van Lijnschoten, I.
    Lemmens, V. E. P. P.
    Slooter, G. D.
    Rutten, H. J. T.
    van den Brule, A. J. C.
    ANALYTICAL CELLULAR PATHOLOGY, 2010, 33 (01) : 1 - 11
  • [5] A phase II study of active specific immunotherapy and 5-FU/Leucovorin as adjuvant therapy for stage III colon carcinoma
    Baars, A
    Claessen, AME
    Wagstaff', J
    Giaccone, G
    Scheper, RJ
    Meijer, S
    Schakel, MJAG
    Gall, HE
    Meijer, CJLM
    Vermorken, JB
    Pinedo, HM
    van den Eertwegh, AJM
    BRITISH JOURNAL OF CANCER, 2002, 86 (08) : 1230 - 1234
  • [6] A prospective randomised trial to study the role of levamisole and interferon alfa in an adjuvant therapy with 5-FU for stage III colon cancer
    Schippinger, W
    Jagoditsch, M
    Sorré, C
    Gnant, M
    Steger, G
    Hausmaninger, H
    Mlineritsch, B
    Schaberl-Moser, R
    Mischinger, HJ
    Hofbauer, F
    Holzberger, P
    Mittlböck, M
    Jakesz, R
    BRITISH JOURNAL OF CANCER, 2005, 92 (09) : 1655 - 1662
  • [7] A prospective randomised trial to study the role of levamisole and interferon alfa in an adjuvant therapy with 5-FU for stage III colon cancer
    W Schippinger
    M Jagoditsch
    C Sorré
    M Gnant
    G Steger
    H Hausmaninger
    B Mlineritsch
    R Schaberl-Moser
    H J Mischinger
    F Hofbauer
    P Holzberger
    M Mittlböck
    R Jakesz
    British Journal of Cancer, 2005, 92 : 1655 - 1662
  • [8] A phase II study of active specific immunotherapy and5-FU/Leucovorin as adjuvant therapy for stage III colon carcinoma
    A Baars
    A M E Claessen
    J Wagstaff
    G Giaccone
    R J Scheper
    S Meijer
    M J A G Schakel
    H E Gall
    C J L M Meijer
    J B Vermorken
    H M Pinedo
    A J M van den Eertwegh
    British Journal of Cancer, 2002, 86 : 1230 - 1234
  • [9] Thymidylate synthase gene polymorphisms effecting 5-FU response in breast cancer patients
    Kumar, Kalyana
    Vamsy, Mohana
    Jamil, Kaiser
    CANCER BIOMARKERS, 2010, 6 (02) : 83 - 93
  • [10] Folinic acid modulated bolus 5-FU or infusional 5-FU for adjuvant treatment of patients of UICC stage III colon cancer:: Preliminary analysis of the PETACC-2-study.
    Carrato, A.
    Köhne, C.
    Bedenne, L.
    Popov, I.
    Bouche, O.
    Gaspar, E.
    Rougier, P.
    Schubert, U.
    Biertz, F.
    Becker, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 161S - 161S
12345